These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8667038)
1. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens. Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038 [TBL] [Abstract][Full Text] [Related]
2. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192 [TBL] [Abstract][Full Text] [Related]
3. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance. Richard MP; Aguado AG; Mattina R; Marre R J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810 [TBL] [Abstract][Full Text] [Related]
5. In-vitro bactericidal activity of four oral antibiotics against pathogens responsible for acute otitis media in children. Lambert-Zechovsky N; Mariani-Kurkdjian P; Doit C; Bourgeois F; Bingen E J Hosp Infect; 1992 Nov; 22 Suppl A():89-97. PubMed ID: 1362754 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Jacobs E; Dalhoff A; Korfmann G Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763 [TBL] [Abstract][Full Text] [Related]
7. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Pontani D; Washton H; Bouchillon S; Johnson J Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284 [TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392 [TBL] [Abstract][Full Text] [Related]
9. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens]. Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240 [TBL] [Abstract][Full Text] [Related]
12. Bactericidal activity and postantibiotic effect of cefdinir (Cl 983, FK 482) against selected pathogens. Blandino G; Caccamo F; Di Marco R; Nicoletti A; Speciale A; Nicoletti G Drugs Exp Clin Res; 1992; 18(8):319-27. PubMed ID: 1292914 [TBL] [Abstract][Full Text] [Related]
13. Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria. Dornbusch K; Olofsson C; Holm S APMIS; 1999 May; 107(5):505-13. PubMed ID: 10335955 [TBL] [Abstract][Full Text] [Related]
14. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Pfaller MA; Farrell DJ; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production. Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715 [TBL] [Abstract][Full Text] [Related]
17. [In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community]. Prado V; Trucco O; Nina A; Salamanca L; Juliet C; Braun S Rev Med Chil; 1995 Nov; 123(11):1394-1401. PubMed ID: 8733283 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria. Louie A; Baltch AL; Ritz WJ; Smith RP Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123 [TBL] [Abstract][Full Text] [Related]
19. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. Odenholt I; Löwdin E; Cars O Antimicrob Agents Chemother; 1997 Nov; 41(11):2522-6. PubMed ID: 9371360 [TBL] [Abstract][Full Text] [Related]
20. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN; J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]